Phase I Study to Assess Irritation, Sensitization and Adhesion of a Novel Ibuprofen 200 mg TEPI Medicated Plaster

A Two-period, Multiple and Single Dose, Randomised, Double-blind, Placebo-controlled, Healthy Volunteer, Phase I Study to Assess Irritation, Sensitization and Adhesion of a Novel Ibuprofen 200 mg TEPI Medicated Plaster

This trial will be conducted with the aim to investigate the dermal response (skin irritation, sensitization) and the adhesion of Ibuprofen 200 mg TEPI Medicated Plaster as compared to a Placebo TEPI Plaster in two phases:

Induction Phase: multiple dose application of one active and one placebo plaster on 5 consecutive days in which the plasters remain in place for 23 hours ± 30 min a day and Challenge Phase: single dose application of one active and one placebo plaster which remain in place for 48 hours ± 30 min.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: Ibuprofen 200 mg TEPI Medicated Plaster; Other: Placebo TEPI Plaster

• Study Type: Interventional
• Enrollment (Actual): 33
• Phase: Phase 1

Contacts and Locations

Study Locations

• Bulgaria
  • Sofia, Bulgaria
    • MHAT

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male and female subject
• Age between 18 and 65 years
• Physically and mentally healthy as judged by means of medical and standard laboratory examinations
• Non-smokers or ex-smokers (stopped at least 6 months ago) with a smoking history of ≤5 pack-year equivalents (1 pack-year equivalent is equal to smoking 1 pack per day for 1 year*****) and non-users of other nicotine containing products, confirmed by urine cotinine test
• Weight ≥ 60 kg and BMI within the range (including the borders) of 18.0 to 30.0 kg/m2
• Informed consent given in written form.

Exclusion Criteria:

• Participation in another clinical trial at same time or within the preceding 90 days (calculated from the date of the final examination of the previous study)
• Fertile women without reliable contraception method. List of allowed medically accepted contraceptive methods and the allowed HRT (used at least 4 weeks prior entry visit and not to be changed for the duration of the study):
• combination of 2 barrier methods: female/male condoms, diaphragms, spermicides
• intrauterine devices (IUD): inert or copper-releasing or progestinreleasing IUD
• hormonal methods: combined oestrogen/progestin injectable contraceptives, progestin only injectable contraceptives, Norplant implants, skin patches, NuvaRing®
• Hormone Replacement Therapy (HRT)
• voluntary sterilization (female tubal occlusion).
• Randomisation into the present trial more than once
• History of drug abuse or use of illegal drugs: use of soft drugs, e.g. marihuana within 6 months of screening or hard drugs, e.g. cocaine, amphetamines, phencyclidine within 1 year of screening
• Alcohol abuse, i.e. regular use of more than 2 units of alcohol per day or 10 units per week or a history of alcoholism (one unit of alcohol equals 250 ml beer, 125 ml wine or 25 ml spirits) or recovered alcoholics
• Positive drug screening and/or positive alcohol test at entry (screening) visit, or on Day -1, or on Day 19
• Pregnant and/or nursing women. Positive pregnancy test at entry (screening) visit, or on Day -1, or on Day 19
• Allergic diathesis or any clinically significant allergic disease (i.e. asthma or bronchial hyper-reactivity, contact dermatitis)
• Known allergy to sticking plaster or to the ingredients of the products
• Dermatologic disease that might interfere with the evaluation of test site reaction
• Active skin disease
• Subjects with tattoos, sunburn, coloration, open sores or scars on site of application
• Subject with excessive hair at site of plaster application
• Intake of systemic drugs interfering with the immune system (e.g. antiinflammatories, corticosteroids, immune-suppressants or antihistamines) within 2 weeks before and during the study
• Topical therapy with analgesics or corticosteroids or antihistamines at the application sites within 2 weeks before and during the study
• Intake or administration of any systemic or topical medication (including prescribed medication, OTC medication, and especially use of ointments, gels or patches for skin application) within 2 weeks before entry (screening) visit and during the study
• Use of topical products without medication at the application sites (including make-up, sunscreen, creams, lotions, powders, alcohol) from 7 days prior entry (screening) visit and during the study
• Intensive UV-light exposure (sunbath) at the application sites within 2 weeks before entry (screening) visit and during the study
• Use of tanning beds at the application sites within 2 weeks before entry (screening) visit and during the study
• Any method of hair removal (e.g. waxing, shaving, epilating, laser) at the application sites from 7 days before entry (screening) visit and during the study
• Presence or a history of clinically significant cardiovascular, renal, hepatic, pulmonary, metabolic, endocrine, haematological, gastrointestinal, neurological, psychiatric or other diseases (e.g. autoimmune disorders such as lupus erythematosus)
• Clinically significant illness within 4 weeks before entry (screening) visit and during the study
• Positive serologic findings for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies [
• Systolic blood pressure outside the range of 100 to 140 mmHg and/or diastolic blood pressure outside the range of 60 to 90 mmHg12 at entry (screening) visit
• Heart rate outside the range of 50 to 90 beats/min at entry (screening) visit
• Respiratory rate outside the range of 12-24 breaths/min at entry (screening) visit
• Axillary body temperature outside the interval of 35.5 to 37.1°C at entry (screening) visit
• Any clinically significant abnormality of the resting ECG (12-lead) (i.e. AV block, 2° to 3°, sinus bradycardia, sick sinus syndrome, SA block)
• Laboratory values outside normal range with clinical relevance at entry (screening) examination
• Not fulfilling study specific restrictions and diet
• Subjects who are known or suspected:
• not to comply with the study directives
• not to be reliable or trustworthy
• not to be capable of understanding and evaluating the information given to them as part of the formal information policy (informed consent), in particular regarding the risks and discomfort to which they would agree to be exposed
• to be in such a precarious financial situation that they no longer weigh up the possible risks of their participation and the inconvenience they may be involved in
• subject is a dependent person, e.g. a relative, family member, or member of the investigator's or sponsor's staff
• subject is in custody or submitted to an institution due to a judicial order.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Test; Ibuprofen 200mg TEPI medicated plaster	Drug: Ibuprofen 200 mg TEPI Medicated Plaster; Ibuprofen 200 mg TEPI Medicated Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK
Placebo Comparator: Placebo; Placebo TEPI Plaster	Other: Placebo TEPI Plaster; Placebo TEPI Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Irritation Score	Average of Dermal Response Scores Score Definition 0 - No evidence of irritation; - Minimal erythema, barely perceptible; - Definite erythema, readily visible; minimal oedema or minimal papular response; - Erythema and papules; - Definite oedema; - Erythema, oedema, and papules; - Vesicular eruption; - Strong reaction spreading beyond test site	10 days
Total Cumulative Irritation Score	Sum of Dermal Response Scores - Score Definition 0 - No evidence of irritation; - Minimal erythema, barely perceptible; - Definite erythema, readily visible; minimal oedema or minimal papular response; - Erythema and papules; - Definite oedema; - Erythema, oedema, and papules; - Vesicular eruption; - Strong reaction spreading beyond test site	10 dyas

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Combined Dermal Response Score	Average of Dermal Response + Other Effects Score Dermal score - as explained above other effect score - Score Definition 0 - None observed; - Slight glazed appearance; - Marked glazing; - Glazing with peeling and cracking; - Glazing with fissures Film of dried serous exudates covering all or part of the plaster site Small petechial erosions and/or scabs	10 days
Total Combined Dermal Response Score	Sum of Dermal Response Score and Other Effects Score Dermal Response score - As explained above Other effects score - As explained above	10 days
Combined Dermal Response Scores	Combined Dermal Response Scores ≥2 Dermal response score - As explained above other effects score - as explained above	10 days

Collaborators and Investigators

• Sponsor: Medherant Ltd
• Collaborators: Cooperative Clinical Drug Research and Development AG (CCDRD AG)

Study record dates

Study Major Dates

• Study Start (Actual): August 9, 2018
• Primary Completion (Actual): October 25, 2018
• Study Completion (Actual): October 25, 2018

Study Registration Dates

• First Submitted: August 16, 2018
• First Submitted That Met QC Criteria: August 20, 2018
• First Posted (Actual): August 21, 2018

Study Record Updates

• Last Update Posted (Actual): April 17, 2019
• Last Update Submitted That Met QC Criteria: April 15, 2019
• Last Verified: April 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Fibrosis; Cicatrix; Tissue Adhesions; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Cyclooxygenase Inhibitors; Ibuprofen
• Other Study ID Numbers: MED-IBU-102

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No